First Trust Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

First Trust Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-30,008	Closed	-$138K	–	2534
2020 Q2	$138K	Buy	30,008 +2,133	+8%	+$9.45K	﹤0.01%	2307
2020 Q1	$92K	Sell	27,875 -5,407	-16%	-$24.7K	﹤0.01%	2300
2019 Q4	$203K	Sell	33,282 -573	-2%	-$2.36K	﹤0.01%	2328
2019 Q3	$141K	Buy	+33,855	New	+$270K	﹤0.01%	2360

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

First Trust Advisors's PHAS Position: Q3 2020 in Review

First Trust Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2020, closing a stake of 30,008 shares — an estimated $138K sold.

First Trust Advisors first reported a position in PHAS in Q3 2019 and held it in 4 quarters. The position peaked at $203K in Q4 2019. 50 funds tracked by Wall St. Rank hold PHAS as of Q3 2020.

First Trust Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
First Trust Advisors sold 30,008 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $138K.
First Trust Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 4 quarters.
First Trust Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $203K in Q4 2019.
50 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on First Trust Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.